Dipna Pharmaceuticals Ltd. engages in the trading and distribution of pharmaceutical raw material and chemical formulation products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2022-09-08. The firm's product portfolio comprises approximately 61 APIs and AIPs intermediates, such as Cephalosporins, Cardiovasculars, Anti - Bactaria, Quinolones, Veterinary, Anti - Virus, Anti - Inflammatory, Neuropsychiatry, Steroid Hormone and others. Its products include Aceclofenac, Asprin, Acetazolamide, Albendazole, Ambroxol HCL, Amisulpride IP/BP, Amoxicillin, Aripiprazole IP, Artemether, Azithromycin, Hydrocortisone Acetate, Ibuprofen Ip, Levofloxacin. Lumefantrine, Lidocaine Base, Lidocaine Hydrochloride, Lornoxicam, L Glutathione Reduced, L Glutamine, L Carnosine, L Arginine Base and others. The company provides import/export services to clients throughout the world.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.
12 fields couldn't be derived. The company was scraped before the cash-flow and balance-sheet rows were captured. Re-running an analysis will refresh these.